* If you want to update the article please login/register
Background: The purpose was to see if tumor response to CPI varies by organ and to map response patterns in a group of surgically treated metastatic RCC patients treated with Nivolumab. Methods: Patients receiving Nivolumab for metastatic RCC were seen between January 2016 and March 2020, a retrospective review was conducted, based on first-line therapy and receiving at least one baseline and two follow-up scans. A Fisher's exact test was used to compare categorical variables, and a Kruskal–Wallis test was used to compare continuous variables. The response rate was highest in adrenal gland lesions, followed by lymph nodes and liver, however lesions in the lung, intraperitoneal metastases, and brain were the lowest in brain lesions. Conclusions: Checkpoint inhibitors in renal cell carcinoma have a patchy response at various metastatic sites, with the best response occurring in lymph nodes and the least occurring in soft tissue.
Source link: https://doi.org/10.3390/tomography8030110
Object Description The authors reviewed Gamma Knife surgery for the treatment of metastatic brain tumors from renal cell carcinoma. Methods The authors' study examined the clinical characteristics and treatment outcomes in 69 patients with metastatic brain tumors from RCC who underwent GKS at the authors' institution. After GKS' analysis of the change in 132 tumors after treatment, followed-up magnetic resonance imaging was used at a median of 7. 1 months. 21. 8 Gy. The mean prescription dose at the tumor margin was 21. 8 Gy. The tumor growth control rate was 86. 6 percent at 82 percent. On univariate and multivariate studies, tumor growth control was highly correlated with tumor growth monitoring. At the time of GKS, sixty of the 132 tumors analyzed by MR imaging were found to have apparent peritumoral edema. The number of lesions at the first GKS, the first GKS's recursive partitioning analysis classification, and the time from diagnosis of RCC to brain metastasis were heavily related with survival time, according to multivariate analysis. Gamma Knife surgery is safe for RCC metastatic brain tumors. The intratumoral edema treatment is highly correlated with the delivery of chemotherapy to the tumor margin. Gamma Knife surgery should be used as the first therapeutic technique, if possible, even in patients with multiple metastases. Because of the poor sensitivity of RCC to conventional radiation therapy, repeated GKS is often used for newly developed brain metastases.
Source link: https://doi.org/10.3171/jns.2006.105.4.555
Objectives: Although several prognostic scores for spinal metastatic disease have been published in the last two decades, the applicability and reliability of these devices to particular cancer types are still unclear. The authors looked at the results of various spinal metastatic disease risk factors in predicting prognosis for spine surgery to treat metastatic renal cell carcinoma in this study. METHODS Patients who underwent RCC metastatic to the spine surgery at two tertiary centers between 2010 and 2019 were retrospectively recovered. After surgery was performed using Cox proportional hazard models, a regression analysis of patient variables in association with 1-year survival was performed. RESULTS A total of 86 metastatic RCC patients were included in the study. CONCLUSIONS The present study reveals that the most cited and commonly used scoring methods have a fair track on patients undergoing spine surgery for metastatic RCC.
Source link: https://doi.org/10.3171/2020.4.spine20173
Metastatic development of clear cell renal cell carcinoma in clear cell carcinoma are complicated. We report a case study in which tumor heterogeneity resulting from clonal mutation is a frequent feature and could have a role in metastatic dissemination. A vein thrombus and two adrenal metastases were classified fourteen specimens from three non-primary sites, including a vein thrombus and two adrenal metastases, using genomic and transcriptomic information to classify fourteen specimens from geographically diverse regions of a kidney tumor and three non-primary sites. Patients with resistance to drugs may be able to benefit from a combination of targeted therapies based on more than one specific clone.
Source link: https://doi.org/10.1136/jclinpath-2020-207326
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions